Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer
Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Karen Kelly(Cancer Research Center), Tiahong Li(UC Davis Comprehensive Cancer Center), David R. Gandara(University of California, Davis), Matthew A. Gubens(University of California, San Francisco), Laurel Beckett(Brigham and Women's Hospital), Primo N. Lara(UC Davis Comprehensive Cancer Center), Ai‐Ming Yu(University at Buffalo, State University of New York), Jonathan W. Riess(University of California Davis Medical Center), Daniel P. Vang(University of California, Davis), Frances Lara, Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 35
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k